Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol

Theramex

Status and phase: Completed; Phase 2

Conditions: Suppression of Ovulation

Treatments: Drug: NOMAC

Study type: Interventional

Funder types: Industry

Identifiers

NCT01361958

96-ESC/NOM-1-RD

Details and patient eligibility

About

The aim of the present study was to evaluate the ability of several doses of NOMAC in combination with E2 to inhibit ovulation and to assess changes in the gonadotropin and ovarian hormone profiles, in comparison to a control cycle in healthy-volunteer premenopausal women.

The study was also designed to check whether the combined administration of E2 and NOMAC at the dose of 2.5 mg daily induces any changes in the effects of the progestin compared to when it is given alone.

Enrollment: 38 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Female premenopausal healthy volunteers having given their informed written consent at the first selection visit,
• Registered with Social Security in agreement with the French Law on biomedical research on volunteers,
• Sufficiently co-operative to meet the needs of the study,
• Accepting not to become pregnant during the trial,
• Accepting the use of condoms as the single authorized contraceptive means during the trial,
• With a diurnal and regular job or activity,
• Aged 18 to 35 years old inclusive,
• Non-smokers or current smokers of less than 10 cigarettes/day,
• With normal eating habits,
• With a body mass index between 17 and 27 inclusive,

Exclusion criteria

• Participation in another clinical trial,
• Blood donation in the three months prior to Visit V1 or intention to donate blood during the trial or within the three months following the trial completion,
• Virgins, because of the gynecological examination,
• Subjects who were within the exclusion period in the Healthy Volunteers National Register of the French Ministry of Health,
• Forfeiture of freedom by administrative or legal award or under guardianship,
• No possible contact in case of emergency,
• Strenuous physical activity planned during the trial. Concerning the gynecological status and examination
• History of major medical, psychiatric illness or surgery,
• Any acute or chronic systemic disease or disorder,
• History of hypersensitivity to at least one drug (abnormal drug reaction or idiosyncrasy or asthma),
• Abuse of alcohol i.e. history or evidence of acute or chronic abuse, more than 45 g of alcohol per day,
• Excessive drinking of tea, coffee, chocolate, and/or beverages containing caffeine (>5 cups/day or approximately 500 mg of caffeine per day),
• Current vascular pathology or with a past history of thrombo-embolic disease, arterial hypertension (BPS ≥ 160 mm Hg or BPD ≥ 95 mm Hg), coronary artery disease, valvulopathy; thrombogenic cardiac rhythm disturbances, cerebrovascular disease, ocular pathology of vascular origin,
• Cancer or progressive hematological disorder,
• Current or past history of pituitary tumors,
• Epilepsy,
• Known hyperprolactinemia,
• Known renal insufficiency,
• Severe or recent liver disease or symptomatic vesicular lithiasis, or recurrent cholestasis or recurring pruritus of pregnancy,
• Abnormality (> 1N) in liver function on the selection laboratory investigation (ALT or AST > 50 IU/L or alkaline phosphatases > 125 IU/L or total bilirubin > 22 μmol/L or GGT > 70 IU/L),
• Known diabetes or fasting blood sugar > 6.2 mmol/L (1N) at the selection laboratory investigation,
• Uncontrolled treated dyslipidemia or cholesterolemia > 5.2 mmol/L (93%N), then > 6.2 mmol/L (110%N) after protocol amendment during the course of the study, or triglyceridemia > 1.80 mmol/L (79 %N) at the selection laboratory investigation,
• Plasma creatinine > 115 μmol/L (1N),
• Abnormality in any of the hematology parameters,
• Positive results at any of the serologies (HBs antigen, HCV antibodies, HIV 1 & 2 antibodies) performed at V1,
• Positive result for β-HCG at any measurements (i.e. β-HCG > 5 mIU/mL),
• Abnormality in the baseline EKG,
• Connective tissue disorder,
• Porphyria,
• Otosclerosis,
• Abnormality at the medical examination performed at V1 which included a neurological examination,
• Past history or clinical evidence of any malignant tumor or benign disease of the breasts or uterus or ovary (including endometriosis, leiomyomas, polycystic ovaries ...),
• Vaginal infection at the vaginal bacteriological examination performed at V1. After protocol amendment during the course of the study, infection diagnosed at the vaginal bacteriology or at the cervico-vaginal smear was removed from the exclusion criteria list.
• Hysterectomy, even partial, or endometrectomy,
• Pregnancy,
• Childbirth, breast-feeding, miscarriage or termination of pregnancy in the year prior to V1,

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

38 participants in 4 patient groups

T1 received 0.625 mg NOMAC + 1.5 mg E2

Experimental group

Treatment:

Drug: NOMAC

T2 received 1.25 mg NOMAC + 1.5 mg E2

Experimental group

Treatment:

Drug: NOMAC

T3 received 2.5 mg NOMAC + 1.5 mg E2

Experimental group

Treatment:

Drug: NOMAC

T4 received 2.5 mg NOMAC + Lactose

Experimental group

Treatment:

Drug: NOMAC